Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lexaria Bioscience (LEXX) Net Margin (2017 - 2025)

Lexaria Bioscience's Net Margin history spans 9 years, with the latest figure at 1551.72% for Q3 2025.

  • For Q3 2025, Net Margin fell 106732.0% year-over-year to 1551.72%; the TTM value through Nov 2025 reached 2068.97%, up 59993.0%, while the annual FY2025 figure was 1685.74%, 43648.0% up from the prior year.
  • Net Margin for Q3 2025 was 1551.72% at Lexaria Bioscience, down from 2183.91% in the prior quarter.
  • Across five years, Net Margin topped out at 22271.71% in Q4 2023 and bottomed at 14359.92% in Q4 2021.
  • The 5-year median for Net Margin is 1468.01% (2024), against an average of 1398.84%.
  • The largest annual shift saw Net Margin soared 2043000bps in 2023 before it tumbled -2080371bps in 2024.
  • A 5-year view of Net Margin shows it stood at 14359.92% in 2021, then skyrocketed by 113bps to 1841.71% in 2022, then skyrocketed by 1109bps to 22271.71% in 2023, then tumbled by -93bps to 1468.01% in 2024, then grew by 6bps to 1551.72% in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Net Margin are 1551.72% (Q3 2025), 2183.91% (Q2 2025), and 1551.72% (Q1 2025).